Figure 3.

Potential targets of HIF/VEGF/DC therapy and FDA approved drugs. Abbreviations: VEGF: vascular endothelial growth factor; DC: dendritic cell; HIF: hypoxia-inducible factor; ROS: reactive oxygen species; TME: tumor microenvironment; NRP1: Neuropilin-1; NF-κB: Nuclear Factor of κ-light-chain-enhancer of activated B cells; MLC: myosin light chain; COF-1: Cofilin1; ERK: extracellular regulated protein kinases; ELCs: endothelial-like cells; TLR: toll-like receptor; EMT: epithelial-mesenchymal transition; LPS: lipopolysaccharide.